CHO-S-Human GUCY2C-Puro
【货号】 |
AKD181A |
【细胞名称】 |
CHO-S-Human GUCY2C-Puro |
【细胞类型】 |
中国仓鼠细胞 |
【过表达基因】 |
Human GUCY2C胞外区 |
【抗性】 |
嘌呤霉素 |
【培养条件】 |
CHOGrow |
【包装规格】 |
3×106 cell/管 |
【运输方式】 |
干冰/常温运输 |
靶点介绍 |
鸟苷酸环化酶C(GUCY2C)是一种跨膜受体型鸟苷酸环化酶,其胞外区含高亲和力配体结合域(识别鸟苷酸、大肠杆菌热稳定肠毒素STa),胞内区由激酶同源调节域(KHD)及羧基末端催化域组成,通过同源二聚化激活后催化GTP生成第二信使cGMP。功能上,GUCY2C-cGMP信号轴经PKGII/磷酸二酯酶调控肠上皮细胞离子转运(CFTR激活)、屏障完整性(紧密连接蛋白组装)、增殖凋亡平衡及DNA损伤修复;新近发现其可被肠内分泌细胞摄取并释放循环激素(如GN、PYY)参与肠-脑轴调控。该受体严格特异性表达于肠上皮细胞顶端刷状缘,在结直肠癌细胞中异常保留且可被Wnt/β-catenin通路上调。临床管线中,GUCY2C是结直肠癌靶向治疗的重要候选。 本品为CHO-S-GUCY2C-Puro过表达细胞株。 |
流式检测 |
图式说明:流式检测CHO-S-GUCY2C-Puro过表达细胞,抗体为Indusatumab |
参考资料 |
1. Lin, J. E., et al. (2016).GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development. 2. Miller, G., et al. (2018).Preclinical evaluation of TAK-164, an antibody-drug conjugate targeting guanylyl cyclase C for gastrointestinal cancers. Molecular Cancer Therapeutics. 3. Fiszer-Maliszewska, L., et al. (2019). Phase I study of TAK-164, a first-in-class GUCY2C-directed antibody-drug conjugate, in patients with advanced gastrointestinal cancers. Journal of Clinical Oncology. 4. Dotan, E., et al. (2024). Novel antibody-drug conjugates in gastrointestinal malignancies: From target selection to clinical translation.Cancer Treatment Reviews. |